×
我们推荐在您的浏览器上开启Javascript,以获得最佳效果。
Kallikrein 11 抗体 (AA 68-82)
KLK11
适用: 人
WB
宿主: 兔
Polyclonal
unconjugated
Kallikrein 11抗体详情
(hide)
抗原
See all Kallikrein 11 (KLK11) 抗体
Kallikrein 11 (KLK11)
抗原表位
All epitopes for Kallikrein 11 抗体
AA 68-82
适用
All reactivities for Kallikrein 11 抗体
人
宿主
All hosts for Kallikrein 11 抗体
兔
克隆类型
All clonalities for Kallikrein 11 抗体
多克隆
标记
All conjugates for Kallikrein 11 抗体
This Kallikrein 11 antibody is un-conjugated
应用范围
All applications for Kallikrein 11 抗体
Western Blotting (WB)
交叉反应
小鼠, 大鼠
交叉反应 (详细)
This antibodys immunogen shares 86 % sequence identity with the Mouse, and rat homologs.
纯化方法
Affinity chromatography purified
免疫原
KLK11 antibody was raised in rabbit using AA 68-82 [YIVHLGQHNLQKEEG] of the 35 kDa human hippostasin/KLK11 protein as the immunogen.
亚型
IgG
Top Product
Discover our top product KLK11 Primary Antibody
Alternatives
(show)
使用细节
(hide)
应用备注
WB: 1:500-1:1,000 Optimal conditions should be determined by the investigator.
限制
仅限研究用
贮存及处理
(hide)
浓度
Lot specific
缓冲液
Affinity purified IgG supplied in PBS with 0.02 % NaN3.
储存液
Sodium azide
注意事项
This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
注意事项
Avoid repeated freeze/thaw cycles. Dilute only prior to immediate use.
储存条件
4 °C/-20 °C
储存方法
Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.
Kallikrein 11目标详情
(hide)
抗原
Kallikrein 11 (KLK11)
别名
KLK11 (KLK11 产品 )
别名
KLK11 antibody, 2310015I08Rik antibody, Prss20 antibody, TLSP antibody, PRSS20 antibody, kallikrein related peptidase 11 antibody, kallikrein related-peptidase 11 antibody, kallikrein-related peptidase 11 antibody, KLK11 antibody, Klk11 antibody
背景
Hippostasin, also known as KLK11, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. Hippostasin plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of hK11 were found in 70% of women with ovarian cancer and in 60% of men with prostate cancer.
途径
Complement System
Recently viewed
(hide)